Showing results (81-90 of 394) with videos related to

Sort By:
Pageof 40
Cells|March 13, 2024
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell TherapyAndreia Maia, Mubin Tarannum, Joana R Lérias, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 13, 2016
Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized TrialsArmin Rashidi, John F DiPersio, Brenda M Sandmaier, et al.
Transfusion|June 18, 2016
Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantationMark A Fiala, Soo Park, Michael Slade, et al.
Transplantation and Cellular Therapy|July 25, 2022
Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving PerspectiveScott R Goldsmith, Armin Ghobadi, John F Dipersio, et al.
Bone Marrow Transplantation|January 26, 2018
Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistanceMarcel van den Brink, Markus Uhrberg, Lorenz Jahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2014
Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cellsJeffrey W Leong, Julie M Chase, Rizwan Romee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 5, 2003
Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host diseaseMichael P Rettig, Julie K Ritchey, Todd E Meyerrose, et al.
Bone Marrow Transplantation|April 19, 2022
Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access programMark A Schroeder, Parameswaran N Hari, Amy Blithe, et al.
Plos One|October 8, 2014
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effectJaebok Choi, Matthew L Cooper, Bader Alahmari, et al.
The American Journal of Managed Care|March 23, 2012
Economic evaluation of plerixafor for stem cell mobilizationSteven M Kymes, Iskra Pusic, Dennis L Lambert, et al.
Pageof 40